Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling
Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling
Liposomal bupivacaine or placebo will be administered at the end of a transobturator
 midurethral sling to determine if there is a difference in a patient's perceived
 postoperative pain.
The investigators aim to evaluate the use of liposomal bupivacaine to reduce postoperative
 pain from placement of transobturator slings for the treatment of stress urinary
 incontinence.
Inclusion Criteria:

 -  Adults > 18 years of age

 -  Planning for outpatient surgical treatment of SUI with placement of a transobturator
 suburethral sling under general anesthesia

 Exclusion Criteria:

 -  Pregnant or nursing

 -  Allergy to bupivacaine

 -  History of drug/alcohol abuse

 -  Severe cardiovascular, hepatic, renal disease, or neurological impairment°

 -  Long-acting opioid within 3 days or any opioid use within 24 hours before surgery

 -  Contraindication to:

 -  acetaminophen

 -  oxycodone

 -  non-steroidal anti-inflammatory drugs (NSAID)

 -  Administration of an investigational drug within 30 days before study

 -  Chronic pain syndromes

 -  Daily NSAID/opioid use

 -  Patients having concomitant procedures or not undergoing general anesthesia

 -  Patients who require a concomitant anterior repair or urethrocele repair will not be
 excluded as this requires the same dissection in the anterior vaginal wall.